All In Biotech

NDA 022138 · Sanofi Aventis US

Lovenox

Enoxaparin Sodium · Injection

Priority review

Last checked: Nov 20, 2026Latest source record: May 16, 2007 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2007

May 16, 2007

Approved uses

1

Original approval plus efficacy supplements

Registered trials

421

139 Phase 3, 34 recruiting

FAERS reports

58,051

50,417 serious, 8,973 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LOVENOX · ENOXAPARIN SODIUM 100MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Enoxaparin" as an intervention, any sponsor and status, largest first.

All 421 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,665
  • dyspnoea2,456
  • nausea2,434
  • diarrhoea2,330
  • anaemia2,259
  • thrombocytopenia2,131
  • pyrexia2,098
  • fatigue2,034
  • vomiting1,905
  • pulmonary embolism1,831
  • death1,772
  • pneumonia1,716

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,257
20051,329
20061,244
20071,240
20081,501
20091,763
20101,941
20112,327
20122,297
20131,935
20142,315
20152,754
20162,904
20172,745
20183,649
20193,436
20203,596
20213,368
20223,956
20233,666
20243,309
20253,268
20262,249

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lovenox (Enoxaparin Sodium)

2024 spending

$577K

Beneficiaries

392

950 claims

Per beneficiary

$1,471

$24.80 per unit

View as table
YearSpending
2020$3,499,490
2021$2,848,286
2022$1,795,726
2023$675,990
2024$576,582

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,199 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.